Acorda On Track To File Oral MS Therapy Fampridine-SR By Q1 2009
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Acorda Therapeutics intends to file an NDA for its oral multiple sclerosis therapy Fampridine-SR in the first quarter of 2009, CEO Ron Cohen said during a Jan. 28 conference call to report cardiac study results for the drug
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.